Royalty Pharma plc - Common Stock (RPRX)

Historical Holders from Q1 2019 to Q4 2025

Type / Class: Equity / Common Stock
Symbol: RPRX on Nasdaq
Shares outstanding: 432,001,939
Price per share: $38.64
All holders as of 30 Sep 2025: Q3 2025
Total 13F shares as of 30 Sep 2025: 327,680,397
Total reported value: $11,559,193,183
% of total 13F portfolios: 0.01%
Share change: -14,399,797
Value change: -$517,301,033
Avg buy value change: +0%
Avg sell value change: -0%
Number of holders: 480
Price from insider filings: $38.42

Reported Shares, Excluding Options vs Price

Reported Value, Excluding Options

Total Investors

Significant Owners of Royalty Pharma plc - Common Stock (RPRX) based on Schedule 13D/G filings

Filer	Ownership	Change %	Holdings Value	Net Change	Nb Shares	Change %	Reporting Name	Report Period
Legorreta Pablo G.	20%		$3,372,819,557		103,112,796		Legorreta G. Pablo	16 May 2025
MORGAN STANLEY	9.2%		$1,289,767,415		38,907,011		Morgan Stanley	30 Jun 2025
Severgnini Achille G.	6.9%	-18%	$956,141,132	-$194,107,912	29,926,170	-17%	Severgnini Achille G.	30 Apr 2025
Capital International Investors	6.6%	+18%	$1,005,907,876	+$190,516,586	28,512,128	+23%	Capital International Investors	30 Sep 2025
FMR LLC	6.5%	-29%	$984,337,180	-$400,247,331	27,900,714	-29%	FMR LLC	30 Sep 2025
BlackRock, Inc.	5.7%		$812,980,977		25,445,414		BlackRock, Inc.	31 Dec 2024
GENERAL ATLANTIC, L.P.	3.2%		$525,313,926		14,243,870		General Atlantic, L.P.	30 Jun 2025
VANGUARD GROUP INC	2.5%		$385,841,061		10,936,538		The Vanguard Group	30 Sep 2025

As of 30 Sep 2025, Royalty Pharma plc - Common Stock (RPRX) has 480 institutional shareholders filing 13F forms. They hold 327,680,397 shares. of 432,001,939 outstanding shares (76%) .

Top 25 institutional shareholders own 57% of the company.

Filer	Ownership	Nb Shares	Share Change %	Portfolio %	Holdings Value
MORGAN STANLEY	10%	44,163,954	-5.2%	0.09%	$1,558,104,371
FMR LLC	6.5%	27,986,714	-31%	0.05%	$987,371,261
Capital International Investors	6.3%	27,212,694	+24%	0.15%	$960,063,844
BlackRock, Inc.	6.1%	26,200,503	+3%	0.02%	$924,353,737
BAILLIE GIFFORD & CO	4%	17,372,502	-3.6%	0.45%	$612,901,870
Swedbank AB	2.8%	12,200,270	+0.35%	0.44%	$430,425,526
ADAGE CAPITAL PARTNERS GP, L.L.C.	2.8%	11,965,633	+99%	0.67%	$422,147,532
VANGUARD GROUP INC	2.5%	10,936,538	-70%	0.01%	$385,841,060
STATE STREET CORP	2.4%	10,272,753	+0.76%	0.01%	$362,422,726
GEODE CAPITAL MANAGEMENT, LLC	1.8%	7,617,413	-6.8%	0.02%	$268,026,898
Caledonia (Private) Investments Pty Ltd	1.7%	7,547,609	+17%	4.3%	$266,279,646
VICTORY CAPITAL MANAGEMENT INC	1.1%	4,657,407	+3.7%	0.1%	$164,313,319
NORTHERN TRUST CORP	0.94%	4,075,239	+1.3%	0.02%	$143,774,431
ARROWSTREET CAPITAL, LIMITED PARTNERSHIP	0.76%	3,282,174	+10%	0.07%	$115,795,099
JANE STREET GROUP, LLC	0.73%	3,151,660	+315%	0.13%	$111,190,565
UBS AM, A DISTINCT BUSINESS UNIT OF UBS ASSET MANAGEMENT AMERICAS LLC	0.72%	3,129,936	-23%	0.02%	$110,424,143
Patient Capital Management, LLC	0.72%	3,117,850	+4.3%	4.4%	$109,997,741
CHARLES SCHWAB INVESTMENT MANAGEMENT INC	0.7%	3,025,712	+0.56%	0.02%	$106,747,119
NEW SOUTH CAPITAL MANAGEMENT INC	0.68%	2,918,263	+1.1%	4.7%	$102,956,319
Legal & General Group Plc	0.65%	2,822,566	+3.8%	0.02%	$99,580,130
BANK OF AMERICA CORP /DE/	0.61%	2,646,772	+30%	0.01%	$93,378,104
Qube Research & Technologies Ltd	0.57%	2,481,771	+737%	0.12%	$87,556,881
Dorsey Asset Management, LLC	0.54%	2,350,449		7.5%	$82,923,841
MILLENNIUM MANAGEMENT LLC	0.52%	2,235,133	+379%	0.06%	$78,855,492
DIMENSIONAL FUND ADVISORS LP	0.49%	2,100,490	+11%	0.02%	$74,104,248

Institutional Holders of Royalty Pharma plc - Common Stock (RPRX) across Reporting Periods

Period	Reported Shares, Excl. Options	Value, Excl. Options	Value Change	Puts Notional Value	Calls Notional Value	Price	Investors
2025 Q4	1,528,505	$59,663,379	+$16,645,667			$38.64	18
2025 Q3	327,680,397	$11,559,193,183	-$517,301,033	$8,890,560	$45,482,976	$35.28	480
2025 Q2	342,210,637	$12,333,363,729	+$949,776,191	$13,824,711	$70,074,747	$36.03	452
2025 Q1	316,670,971	$9,861,159,169	-$37,985,860	$29,287,104	$76,794,597	$31.13	442
2024 Q4	320,448,340	$8,176,924,966	+$265,158,717	$3,002,527	$12,951,427	$25.51	411
2024 Q3	306,999,519	$8,678,267,750	-$212,176,487	$1,343,775	$16,337,475	$28.29	389
2024 Q2	316,064,863	$8,332,165,860	+$242,450,037	$3,644,334	$7,903,089	$26.37	373
2024 Q1	307,368,599	$9,329,146,516	+$5,409,040	$7,164,283	$8,215,085	$30.37	371
2023 Q4	6,094,339	$171,190,263	+$24,400,125			$28.09	7
2023 Q3	243,733,971	$6,616,242,757	-$572,216,349	$5,037,184	$31,135,334	$27.14	305
2023 Q2	245,565,120	$7,554,175,890	-$135,762,661	$2,597,530	$13,012,242	$30.74	313
2023 Q1	298,092,085	$10,739,372,277	+$36,500,380	$1,952,691	$15,348,780	$36.03	325
2022 Q4	296,922,817	$11,727,968,685	+$80,318,023	$3,045,777	$18,894,512	$39.52	326
2022 Q3	292,031,779	$11,735,955,735	+$248,974,686	$3,596,687	$45,391,000	$40.18	299
2022 Q2	285,594,162	$11,991,037,676	+$879,862,424	$2,793,369	$43,273,734	$42.04	272
2022 Q1	263,770,078	$10,278,621,867	+$68,249,059	$3,550,000	$35,649,000	$38.96	264
2021 Q4	265,420,556	$10,577,082,827	+$209,537,047	$9,258,000	$38,559,000	$39.85	249
2021 Q3	260,736,943	$9,423,303,775	+$494,381,045	$9,836,276	$33,956,000	$36.14	221
2021 Q2	248,270,446	$10,176,063,385	+$90,937,218	$13,094,236	$30,797,000	$40.99	225
2021 Q1	244,921,369	$10,683,044,688	+$825,962,221	$11,079,236	$42,133,000	$43.62	204
2020 Q4	225,086,395	$11,265,254,059	+$1,960,214,787	$38,699,000	$17,069,000	$50.05	183
2020 Q3	154,682,945	$6,496,244,173	+$400,661,780	$6,150,000	$4,367,000	$42.07	128
2020 Q2	146,090,335	$7,034,389,503	+$7,033,778,960	$1,544,000	$2,617,000	$48.55	118
2020 Q1	15	$1,000	$0			$66.67	1
2019 Q4	15	$1,000	$0			$66.67	1
2019 Q3	15	$1,000	$0			$66.67	1
2019 Q2	15	$1,000	$0			$66.67	1
2019 Q1	15	$1,000	$0			$66.67	1